- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Shift to Value-Based Kidney Care Delivery in 2021
On this episode of Managed Care Cast, we speak with the new chief financial officer of Strive Health, a value-based kidney care company that works with payers and providers to create an integrated care delivery system for chronic kidney disease and end-stage renal disease (ESRD). We discuss the changes coming to nephrology practices, as well as new ways of looking at the whole patient to halt the slide to irreversible ESRD.
In 2021, CMS is launching new payment models to address the high cost of care for Medicare beneficiaries with kidney disease and to improve patient outcomes. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are among the most expensive conditions in Medicare; about 37 million Americans have CKD and 725,000 have ESRD. The situation is expected to get worse as the population ages, rates of diabetes and obesity soar, and demand for dialysis increases.
On this episode of Managed Care Cast, we speak with Brandi Riddle, who recently joined Strive Health as its chief financial officer. Strive Health is a value-based kidney care company that works with payers and providers to create an integrated care delivery system for CKD and ESRD. We discuss the changes coming to nephrology practices, as well as new ways of looking at the whole patient to try and halt the slide to irreversible ESRD.
Listen above or through one of these podcast services:
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
